

Exhibit U

Sent: 10/6/2023 4:54:44 AM
From: Minetta Liu <mliu@natera.com>
To: "Howard"
Cc:
Bcc:
Importance: Normal
Subject: Re: COBRA
Attachments: [image001.png](#), [image002.png](#)

Thank you so much, Howard.

On Thu, Oct 5, 2023 at 4:14 PM Howard Hochster <hh458@cinj.rutgers.edu> wrote:

Hi Minetta,

Per the NRG leadership, they need to go through a few more steps and meetings with NCI before they can consider this. But they are interested. Will circle back when I hear more. Many thanks.

HH

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers RWJ Medical School

Rutgers-CINJ Associate Director, Clinical Research

Director Clinical Oncology Research, RWJBHealth System

195 Little Albany Street, Room 2004

New Brunswick, NJ 08903

Tel 732-235-5912 (FAX – 6797)

email: howard.hochster@rutgers.edu



From: Minetta Liu <mliu@natera.com>
Date: Thursday, October 5, 2023 at 2:33 PM
To: Howard Hochster <hh458@cinj.rutgers.edu>
Subject: Re: COBRA

Hi Howard.

A virtual meeting would be great. Would you kindly connect the dots for us?

Take care,

Minetta

On Mon, Oct 2, 2023 at 8:42 AM Howard Hochster <hh458@cinj.rutgers.edu> wrote:

Thanks Minetta. I spoke with Thom George and Norm Wolmark. Should we plan a virtual meeting ?

HH

Howard S. Hochster, MD
CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

195 Little Albany Street, Room 2004
New Brunswick, NJ 08903
Tel 732-235-5912

Fax 732-235-6797

email: howard.hochster@rutgers.edu

Sent from my iPhone

On Oct 2, 2023, at 09:02, Minetta Liu <mliu@natera.com> wrote:

Dear Howard,

Thank you for your message, and for helping to educate providers about the value of tumor-informed MRD testing. Natera would certainly consider what you propose re: COBRA. With whom among the NRG leadership team did you discuss this? Happy to engage as you see fit.

Take care,

Minetta

Minetta C. Liu, MD

Chief Medical Officer, Oncology

MLIU@natera.com

M: (+1) 507-261-0884



On Tue, Sep 26, 2023 at 1:01 PM Howard Hochster <hh458@cinj.rutgers.edu> wrote:

Hi Minetta.

Thank you for sending out this email on the COBRA trial. This is a critical point which I keep emphasizing to people. Their methylation signature is “poo-poo”.

I have mainly dealt with Mike Krainock, but wanted to see if you would consider re-running the tissue and blood for these patients. I have brought this up to NRG leadership team.

HH

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers RWJ Medical School

Rutgers-CINJ Associate Director, Clinical Research

Director Clinical Oncology Research, RWJBHealth System

195 Little Albany Street, Room 2004

New Brunswick, NJ 08903

Tel 732-235-5912 (FAX – 6797)

email: howard.hochster@rutgers.edu

Error! Filename not specified.

Error! Filename not specified.



